Revance Therapeutics, Inc. (RVNC)

NASDAQ: RVNC · IEX Real-Time Price · USD

3.570

-0.090 (-2.46%)

At close: Apr 24, 2024, 4:00 PM

3.710

+0.140 (3.92%)

After-hours: Apr 24, 2024, 5:10 PM EDT

Revance Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2011
Cash & Equivalents	137.88	108.97	115.67	337	171.89	73.99	283.48	64.08	201.65	171.11	Upgrade
Short-Term Investments	116.59	231.74	114.45	102.95	118.96	102.56	0	122.03	50.69	0	Upgrade
Cash & Cash Equivalents	254.47	340.71	230.12	439.95	290.85	176.54	283.48	186.11	252.34	171.11	Upgrade
Cash Growth	-25.31%	48.06%	-47.69%	51.27%	64.75%	-37.72%	52.32%	-26.25%	47.47%	4189.47%	Upgrade
Receivables	27.68	11.34	3.35	1.83	0	27	0.05	0	0	0	Upgrade
Inventory	45.58	18.33	10.15	5.88	0	0	0	0	0	0	Upgrade
Other Current Assets	11.15	4.36	2.5	2.35	5.76	4.38	1.69	6.59	1.63	1.62	Upgrade
Total Current Assets	338.87	374.73	246.12	450	296.6	207.92	285.21	192.7	253.96	172.73	Upgrade
Property, Plant & Equipment	90.21	59.42	69	47.13	41.29	14.45	9.25	10.59	19.71	19.27	Upgrade
Long-Term Investments	6.87	6.05	0	0	0	0	0	0	2.15	0.44	Upgrade
Goodwill and Intangibles	9.81	112.52	202.3	218.31	0	0	0	0	0	0	Upgrade
Other Long-Term Assets	32.7	29.19	13.75	4.78	2.4	3.98	1.24	1.08	0	0.03	Upgrade
Total Long-Term Assets	139.59	207.17	285.05	270.22	43.69	18.43	10.49	11.67	21.86	19.74	Upgrade
Total Assets	478.45	581.9	531.16	720.22	340.29	226.35	295.7	204.36	275.82	192.47	Upgrade
Accounts Payable	13.81	4.55	10.6	12.66	8.01	8.43	6.81	3.75	2.66	3.15	Upgrade
Deferred Revenue	81.16	85.44	83.51	85.15	55.86	51.27	0	0	0	0	Upgrade
Current Debt	10.85	4.91	4.75	4.44	3.47	0	1.87	3.48	3.14	2.94	Upgrade
Other Current Liabilities	-16.6	-19.22	-31.57	-41.28	-26.36	-27.74	12.23	12.42	6.25	4.15	Upgrade
Total Current Liabilities	89.22	75.68	67.29	60.96	40.98	31.97	20.9	19.65	12.04	10.24	Upgrade
Long-Term Debt	467.58	413.56	319.77	207.67	25.87	0	0	1.87	5.35	0.6	Upgrade
Other Long-Term Liabilities	73.25	80.06	75.64	77.29	47.95	48.76	5.95	5.77	5.19	5.27	Upgrade
Total Long-Term Liabilities	540.83	493.62	395.4	284.97	73.82	48.76	5.95	7.64	10.53	5.86	Upgrade
Total Liabilities	630.06	569.3	462.69	345.93	114.8	80.73	26.85	27.29	22.57	16.1	Upgrade
Total Debt	478.43	418.47	324.51	212.11	29.34	0	1.87	5.35	8.48	3.54	Upgrade
Debt Growth	14.33%	28.95%	52.99%	622.93%	-	-	-64.99%	-36.95%	139.58%	-86.11%	Upgrade
Retained Earnings	-2,078.36	-1,754.37	-1,397.95	-1,126.29	-844.2	-684.78	-542.17	-421.54	-332.27	-258.8	Upgrade
Comprehensive Income	0.01	-0.37	-0.02	0	0	-0.01	0	-0.05	-0.04	0	Upgrade
Shareholders' Equity	-151.6	12.6	68.47	374.29	225.49	145.62	268.85	177.07	253.25	176.37	Upgrade
Net Cash / Debt	-223.97	-77.76	-94.4	227.84	261.51	176.54	281.6	180.76	243.86	167.57	Upgrade
Net Cash / Debt Growth	-	-	-	-12.87%	48.13%	-37.31%	55.79%	-25.87%	45.53%	-	Upgrade
Net Cash Per Share	-2.65	-1.07	-1.40	3.93	6.02	4.88	9.36	6.43	10.02	8.64	Upgrade
Working Capital	249.64	299.05	178.83	389.04	255.62	175.95	264.31	173.05	241.93	162.5	Upgrade
Book Value Per Share	-1.79	0.17	1.01	6.45	5.19	4.03	8.93	6.30	10.40	9.10	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).